MedImmune adds VPs
Executive Summary
MedImmune promotes three employees to newly created VP posts: Cynthia Oliver to VP of process biochemistry and formulation sciences; Kripa Ram to VP of bioprocess and manufacturing sciences; and Mark Schenerman to VP of analytical biochemistry. The company also hires Jessie Groothuis as VP and head of medical & scientific affairs, infectious disease. She will be responsible for the late-stage clinical programs for MedImmune's marketed infectious disease products, such as Synagis (palivizumab) and FluMist...
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: